Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience.

The benefit in post-menopausal patients was confirmed by a meta -analysis published by the Early Breast Cancer Trialists Collaborative Group in 2015 [11] , which revealed that among 11,767 post-menopausal women (including pre-menopausal women on ovarian suppression), adjuvant BPs produced highly significant reductions in BC recurrence (HR 0.86, 95% CI 0.78–0.94; 2p = 0.002), distant recurrence (HR0.82, 0.74–0.92; 2p = 0.0003), bone recurrence (HR 0.72, 0.60–0.86; 2p = 0.0002) and importantly, BC mortality (HR 0.82, 0.73–0.93; 2p = 0.002).

also in 132,142 other papers